글로벌 앤젤만 증후군 치료 시장 – 2030년까지의 산업 동향 및 예측

앤젤만 증후군 치료 시장 분석 및 규모

엔젤만 증후군의 발생률은 인구와 연령대에 따라 다를 수 있습니다. 그러나 엔젤만 증후군에 대한 치료 옵션을 개발하기 위한 정부 이니셔티브의 증가는 글로벌 엔젤만 증후군 치료 시장을 주도합니다. 게다가 건강 및 R&D 지출 증가도 시장 성장을 촉진합니다.  

Data Bridge Market Research는 2022년에 1억 4,377만 달러였던 엔젤만 증후군 치료 시장이 2030년까지 2억 2,064만 달러로 급증할 것이며 예측 기간 동안 5.5%의 CAGR을 경험할 것으로 분석했습니다. 이는 시장 가치를 나타냅니다. "물리 치료"는 치료를 위한 더 나은 수술적 방법에 대한 수요가 증가함에 따라 엔젤만 증후군 치료 시장의 치료 부문을 지배하고 있습니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

앤젤만 증후군 치료 시장 범위 및 세분화

Market Definition

Angelman syndrome is a very rare genetic disorder that affects the nervous system. This syndrome is caused by a loss of function in the UBE3A gene on the maternal 15th chromosome. People suffering from angelman disorder have excitable personalities and they frequently laugh and smile. Major symptoms of angelman syndrome are lack of speech, balance issues and seizures. Sometimes tongue thrusting, Jerky movement may occur.

Global Angelman Syndrome Treatments Market Dynamics

Drivers

• Rising prevalence of speech disorders

The rising prevalence of speech disorders such as stuttering, apraxia, and others among children and adults is expected to fuel the global angelman syndrome treatments market. Furthermore, the rising prevalence of chronic illnesses such as brain injuries, tumours, Parkinson's disease, autism, cerebral palsy and stroke is also expected to drive the global angelman syndrome treatments market. Expressive disorders, voice disorders, articulation disorders, fluency disorders, and language disorders such as receptive disorders and cognitive-communication disorders are all instances of speech disorders. The emergence of these disorders is boosting the global angelman syndrome treatments market.

• Increasing investment in healthcare infrastructure

Another significant factor influencing the growth rate of angelman syndrome treatments market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Opportunities

• Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the angelman syndrome treatments and will further create lucrative market growth opportunities. Research and development proficiencies being conducted to provide best of the medications to curb the Angelman Syndrome is also bolstering the market growth rate.

• Increase in the number of research and development activities       

The increase in the number of research and development activities is estimated to provide various beneficial opportunities for the neurological disorder drugs market’s growth. New therapeutic techniques for the treatment of angelman syndrome are being adopted by companies in the neurological disorder pharmaceuticals market. This leads to high number of research activities to better understand the disease's genetic risk factors in order to find better drugs.

Restraints/Challenges

• Hight costs associated with the research and development activities

The high cost associated with the research and development activities will obstruct the growth rate of market

This angelman syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Angelman Syndrome Treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Development

• In September 2021, Sumitomo Dainippon Pharma and Otsuka announced a collaboration as well as license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations.

Global Angelman Syndrome Treatment Market Scope

The angelman syndrome treatment market is segmented on the basis of treatment, service provider, diagnostic test and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Physical Therapy
• Communication Therapy
• Behavior Therapy
• Others

 Service Provider

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Diagnostic Test

• DNA methylation test
• Chromosomal Microarray (CMA)
• Gene mutation Tests
• Other

End Users

• Clinic
• Hospital
• Others

Global Angelman Syndrome Treatment Market Regional Analysis/Insights

The global angelman syndrome treatment market is analysed and market size insights and trends are provided by country, treatment, service provider, diagnostic test and end-users as referenced above.

The countries covered in the angelman syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the angelman syndrome treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having Angelman Syndromes such as moles, warts and skin tags.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The angelman syndrome treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Angelman Syndrome treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Angelman Syndrome market.

Competitive Landscape and Angelman Syndrome Treatment  Market Share Analysis

엔젤만 증후군 치료 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭 및 범위, 응용 프로그램 우세입니다. 제공된 위의 데이터 포인트는 엔젤만 증후군 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

엔젤만 증후군 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 스마트 스피치 테라피(미국)

• 스피치 테라피 솔루션 주식회사(미국)

• Talk Speech and Language Therapy Ltd. (영국)

• 글렌다 브라운 언어병리학(호주)

• 벤치마크 테라피즈(Benchmark Therapies, Inc) (미국)

• 스피치 플러스(미국)

• 통합 치료 서비스(미국)

• Speechworks Therapy Services (미국)

• 아카펠라 그룹(벨기에)

• Advanced Voice Recognition Systems, Inc. (미국)

• 오픈 텍스트 코퍼레이션(캐나다)

• 클리블랜드 클리닉(미국)

• Therapy Solutions Inc (미국)

• 머크 KGaA(독일)

• 에자이 주식회사(일본)

• 아스트라제네카(영국)

• 사노피(프랑스)

• 노바티스 AG(스위스)

• 애벗(미국)

• F. 호프만-라 로슈 유한회사(스위스)

• Teva Pharmaceutical Industries Ltd. (아일랜드)

• 파이저 주식회사(미국)

• GlaxoSmithKline plc (영국)

SKU-60302